Patients assessed for eligibility (n=47)

Excluded (n=5)
- Declined to participate (n=3)
- Other reasons (n=2)

Randomized (n=42)

Allocated to study drug (n=23)

Follow-up
- Week 28 (n=21)
- Week 52 (n=19)

Analysed (n=19)
- Excluded from analysis:
  - Lost to follow up (n=2)
  - Consent withdrawn (n=2)

Allocated to placebo (n=19)

Follow-up
- Week 28 (n=16)
- Week 52 (n=16)

Analysed (n=15)
- Excluded from analysis:
  - Lost to follow up (n=1)
  - Lack of efficacy (n=1)
  - Consent withdrawn (n=2)